A Phase 3 interventional study of Baloxavir Marboxil in Influenza, sponsored by Hoffmann-La Roche. Completed at 27 sites in 9 countries. Open to participants aged Up to 1 Year. Per ClinicalTrials.gov, last updated 2024-05-17.
Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies testing baloxavir in Influenza, Human — 7 open to participants now, 7 under way, 5 of them phase 3. baloxavir · Influenza, Human.
Among the 18 studies testing baloxavir in Influenza, Human, this one is the 17th largest by enrollment, is one of 4 that started in 2019, is one of 12 in phase 3, and was the 5th registered.
2,358 studies on the registry are indexed under Influenza, Human; 184 are open to participants now.
Browse Influenza, Human studies →7 of the 18 studies testing baloxavir in Influenza, Human are open now, in 12 countries. Recruiting first, the newest first:
Hoffmann-La Roche · Sites in China
Ages 5+ · Healthy volunteers
Unity Health Toronto · Sites in Canada
Ages 18+
Dre Pauline Vetter · Sites in Switzerland
Ages 18+
Hoffmann-La Roche · Sites in United States, Bulgaria, Poland and 1 more country
Ages 3 wk–11 yrs
University of Oxford · Sites in Brazil, Laos, Nepal and 1 more country
Ages 18–60
By country, each count listing its studies:
baloxavir: first FDA approval 2018 (XOFLUZA), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →
Of the 121 Influenza, Human studies recruiting now, 66 (55%) set no upper age limit and 45 (37%) stop at 75 or younger; 33 take children under 18; 67 take healthy volunteers.
This study: Up to 1 Year · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 2 · Phase 3 13 · Phase 4 3
First in 2016; this study’s year is marked. 4 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 49 is below the median of 227 across 1,957 interventional studies indexed under Influenza, Human.
Median enrollment 483 across the 18 interventional studies. Of the 10 that completed or were terminated, 8 (80%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 18 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
22 studies in Influenza, Human by Hoffmann-La Roche: 2 open now, 2 under way, 2 of them phase 3. Of 20 finished, 16 (80%) have results posted.
Among the 22 studies in Influenza, Human by Hoffmann-La Roche, this one is the 15th largest by enrollment of the 19 interventional ones that give a count, is one of 3 that started in 2019, is one of 10 in phase 3, and was the 17th registered.
Hoffmann-La Roche’s Influenza, Human studies by the year they started, since 2006.
5 of the studies testing baloxavir in Influenza, Human that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07314905Phase 3Unity Health TorontoAdaptive Platform Trial of Treatments for Respiratory Infections in Community Settings (TreatResp) | 2027-03-31 |
| NCT06653569Phase 3Dre Pauline VetterEfficacy of Baloxavir Against Influenza in Hospitalized Patients: The INFLUENT Study (INpatients inFLUENza Treatment) | 2027-04 |
| NCT07827599Phase 3Hoffmann-La RocheA Study to Confirm Efficacy of a Single Dose of Baloxavir Marboxil in the Post-exposure Prophylaxis (PEP) of Influenza Virus Infection in Chinese Participants | 2027-04-30 |
| NCT06094010Phase 3Hoffmann-La RocheA Surveillance Study of Susceptibility to Baloxavir Marboxil in Pediatric Participants With Influenza and Transmission of Influenza to Household Contacts | 2027-05-11 |
| NCT05648448University of OxfordA Phase 2 Trial Comparing Antiviral Treatments in Early Symptomatic Influenza | 2027-01-01 |
Add all 5 to your calendar (.ics) → With an account.
Among the 18 studies testing baloxavir in Influenza, Human, from their registry updates:
Among Hoffmann-La Roche’s 22 in Influenza, Human:
This tab as a report to print or save as PDF → With an account.
This study will evaluate the safety, pharmacokinetics and efficacy of baloxavir marboxil in healthy pediatric participants from birth to \<1 year with influenza like symptoms
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants with a diagnosis of influenza virus infection confirmed by the presence of all of the following:
(b) Positive prescreening influenza test (RIDT or PCR) performed within 48 hours of screening
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive single oral dose of baloxavir marboxil on Day 1 (based on body weight and age).
Drug: Baloxavir Marboxil
Participants will receive single oral dose of baloxavir marboxil on Day 1 based on body weight and age. Participants aged ≥ 3 months to \<12 months old received baloxavir marboxil, 2 milligrams per kilograms (mg/kg). Participants from birth to \< 4 weeks old and ≥ 4 weeks to \< 3 months old received baloxavir marboxil, 1 mg/kg.
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
An AE is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not considered related to the medicinal (investigational) product. A SAE is any significant hazard, contraindication, side effect that is fatal or life-threatening, requires hospitalization or prolongation of an existing hospitalization, results in persistent or significant disability/ incapacity, is a congenital anomaly/ birth defect, is medically significant or requires intervention to prevent one or other of the outcomes listed above.
Time frame: From Day 1 up to Day 29
Plasma Concentrations of Baloxavir Marboxil and S-033447
S-033447 is an active metabolite of baloxavir marboxil.
Time frame: 0.5 to 2 hours post dose on Day 1; 24 hours (Day 2) and 72 hours (Day 4) post dose, Day 6 and Day 10
Area Under the Concentration to Time Curve From Time 0 to Infinity (AUC0-inf) of Baloxavir Marboxil and S-033447
S-033447 is an active metabolite of baloxavir marboxil.
Time frame: Up to Day 10
Maximum Plasma Concentration (Cmax) of Baloxavir Marboxil and S-033447
S-033447 is an active metabolite of baloxavir marboxil.
Time frame: Up to Day 10
Time to Maximum Plasma Concentration (Tmax) of Baloxavir Marboxil and S-033447
S-033447 is an active metabolite of baloxavir marboxil.
Time frame: Up to Day 10
Apparent Half-Life (T1/2) of Baloxavir Marboxil and S-033447
S-033447 is an active metabolite of baloxavir marboxil.
Time frame: Up to Day 10
Time to Alleviation of Influenza Signs and Symptoms
Time to alleviation of influenza signs and symptoms was defined as the length of time taken from the start of treatment to the point at which all of the following criteria were met and remained for at least 21.5 hours: * A score of 0 (no problem) or 1 (minor problem) for cough and nasal symptoms for items 14 and 15 of the Canadian Acute Respiratory Illness and Flu Scale \[CARIFS\]); * A "yes" response to the following question on the CARIFS: "Since the last assessment has the participant been able to return to day care/school, or resume his or her normal daily activity in the same way as performed prior to developing the flu?"; * First return to afebrile state (tympanic temperature ≤37.2 degree Celsius \[°C\]). Median time was estimated from the Kaplan-Meier curve. Participants who withdrew prior to an event of interest or did not experience resolution of symptoms were censored at the last observation time point.
Time frame: Day 1 up to Day 15
Duration of Fever
Duration of fever was defined as the length of time taken by participants to return to afebrile state \[tympanic temperature ≤ 37.2°C\] and remaining so for at least 21.5 hours after onset. Participants who did not have fever at baseline or whose body temperature was not collected were excluded from the analysis. Median time was estimated from the Kaplan-Meier curve.
Time frame: Day 1 up to Day 15
Duration of Symptoms
The efficacy of baloxavir marboxil was evaluated by duration of symptoms i.e., alleviation of all symptoms as defined by a score of 0 \[no problem\] or 1 \[minor problem\] and remaining so for at least 21.5 hours, for all 18 symptoms (Poor appetite; Not sleeping well; Irritable, cranky, fussy; Feels unwell; Low energy, tired; Not playing well; Crying more than usual; Needing extra care; Clinginess; Headache; Sore throat; Muscle aches or pains; Fever; Cough; Nasal congestion, runny nose; Vomiting; Not interested in what's going on; Unable to get out of bed) specified in the CARIFS questionnaire. Median time was estimated from the Kaplan-Meier curve. Participants who withdrew prior to an event of interest or did not experience resolution of symptoms were censored at the last observation time point.
Time frame: Day 1 up to Day 15
Time to Return to Normal Health and Activity
Time to return to normal health and activity was defined by a 'Yes' response to the following question on the CARIFS: "Since the last assessment has the patient been able to return to day care/school or resume his or her normal daily activity in the same way as performed prior to developing the flu?" and remaining so for at least 21.5 hours. Median time was estimated from the Kaplan-Meier curve.Participants who withdrew prior to an event of interest or did not experience resolution of symptoms were censored at the last observation time point.
Time frame: Day 1 up to Day 15
Number of Participants With Influenza-Related Complications
The influenza related complications include death, hospitalization, radiologically confirmed pneumonia, bronchitis, sinusitis, otitis media, encephalitis/encephalopathy, febrile seizures, myositis
Time frame: Day 1 up to Day 29
Number of Participants Requiring Antibiotics
The number of participants who required antibiotics for influenza related complication are reported here.
Time frame: Day 1 up to Day 29
Time to Cessation of Viral Shedding by Virus Titer
Time to cessation of viral shedding by virus titer was defined as the time, in hours, between the initiation of any study treatment and first time when the influenza virus titer was below the limit of detection (0.75 log10 tissue culture infectious dose (TCID)50/milliliters \[mL\]). Participants whose virus titers did not reach the limit by the last observation time point were treated as censored at that time point. One day was converted into 24 hours. Median time was estimated from the Kaplan-Meier curve.
Time frame: Day 1 up to Day 29
Time to Cessation of Viral Shedding by Reverse Transcription-Polymerase Chain Reaction (RT-PCR)
Time to cessation of viral shedding by RT-PCR, in hours, was defined as the time between the initiation of study treatment and first time when the virus ribonucleic acid (RNA) by RT-PCR qualitative result was negative (no cycle threshold \[Ct\]-value detectable). Participants who did not have a negative result by the last observation time point were treated as censored at that time point. For the participants with multiple virus types, this endpoint was defined as the time between the initiation of the study treatment and first time when the virus RNA by RT-PCR qualitative result was negative for all virus types. One day was converted into 24 hours. Median time was estimated from the Kaplan -Meier curve. Participants with a positive virus RNA on Day 1 are included in this analysis.
Time frame: Day 1 up to Day 29
Change From Baseline in Influenza Virus Titer Over Time
Change from baseline in influenza virus titer (log10TCID50/mL) was defined as the change from baseline in influenza virus titer on Days 2, 4, 6, 10, and 29. If influenza virus titer was less than the lower limit of quantification (LLOQ), the virus titer was imputed as 0.749 (log10TCID50/mL). Only participants with a positive virus titer on Day 1 were included in this analysis.
Time frame: Baseline, Days 2, 4, 6, 10, and 29
Change From Baseline in the Amount of Virus RNA (RT-PCR) Over Time
Change from baseline in the amount of virus RNA was defined as the change from baseline in the amount of virus RNA on Days 2, 4, 6 and 10. If the amount of virus RNA is less than the lower limit of quantification, the amount of virus RNA was imputed as the relevant LLOQ (log10 viral particles per mililiter (vp/mL)). If a participant was infected with multiple virus types, the sum of virus RNA (log10 vp/mL) was used for analysis. Participants with a positive virus RNA by RT-PCR on Day 1 were included in this analysis.
Time frame: Baseline, Days 2, 4, 6, and 10
Percentage of Participants With Positive Influenza Virus Titer Over Time
Percentage of participants positive for influenza virus titer at each visit were defined as the percentage of participants whose influenza virus titer was not less than the LLOQ (0.75 log10TCID50/mL) or positive among those assessed for influenza virus titer on Days 2, 4, 6, 10 and 29. Participants with a positive influenza virus titer on Day 1 were included in this analysis.
Time frame: Baseline, Days 2, 4, 6, 10, and 29
Percentage of Participants Positive by RT-PCR Over Time
Percentage of participants positive by RT-PCR at each visit was defined as the percentage of participants with a positive qualitative result among those assessed by RT-PCR on Days 2, 4, 6, 10 and 29. Participants with a positive RT-PCR result on Day 1 were included in this analysis. Percentages are rounded off.
Time frame: Baseline, Days 2, 4, 6, 10, and 29
Area Under the Concentration-Time Curve (AUC) in Virus Titer
AUC in virus titer was calculated using the trapezoidal method. Twenty-four hours of time was converted into one day. Participants with a positive virus titer on Day 1 were included in this analysis. The LLOQ and lower limit of detection was defined as 0.75 log10TCID50/mL for flu A and 0.75 log10TCID50/mL for flu B. If a participant was infected with multiple virus types, the sum of those virus titers will be used for analysis.
Time frame: Day 1 up to Day 29
Area Under the Curve in the Amount of Virus RNA (RT-PCR)
AUC in virus RNA (RT-PCR) was defined as AUC of change from baseline in the amount of virus RNA (RT-PCR). AUC was calculated using the trapezoidal method similar to AUC in virus titer. Participants with a positive RT-PCR result on Day 1 were subjected to this analysis. If the amount of virus RNA is less than the lower limit of quantification, the amount of virus RNA was imputed as the relevant LLOQ (log10 viral particles per mililiter (vp/mL)). If a participant was infected with multiple virus types, the sum of those the amount of virus RNA was used for analysis.
Time frame: Day 1 up to Day 29
Participants were enrolled in this study at 15 investigative sites in 7 countries (Costa Rica, Finland, Mexico, Poland, South Africa, Spain, and the United States) from 23 January 2019 to 03 April 2023.
| Milestone | Baloxavir Marboxil |
|---|---|
| Started | 49 |
| Completed | 46 |
| Not completed | 3 |
| Withdrew: Withdrawal by subject | 1 |
| Withdrew: Enrolled in error | 1 |
| Withdrew: Death | 1 |
An AE is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not considered related to the medicinal (investigational) product. A SAE is any significant hazard, contraindication, side effect that is fatal or life-threatening, requires hospitalization or prolongation of an existing hospitalization, results in persistent or significant disability/ incapacity, is a congenital anomaly/ birth defect, is medically significant or requires intervention to prevent one or other of the outcomes listed above.
| Participants | Baloxavir Marboxil |
|---|---|
| AEs | 23 |
| SAEs | 2 |
S-033447 is an active metabolite of baloxavir marboxil.
| nanograms per milliliters (ng/mL) | Baloxavir Marboxil |
|---|---|
| Baloxavir Marboxil: 0.5 to 2 hours | 0.93 ± 2.301 |
| Baloxavir Marboxil: 24 hours | 0 ± 0 |
| Baloxavir Marboxil: 72 hours | 0 ± 0 |
| Baloxavir Marboxil: Day 6 | 0 ± 0 |
| Baloxavir Marboxil: Day 10 | 0 ± 0 |
| S-033447: 0.5 to 2 hours | 81.98 ± 89.412 |
| S-033447: 24 hours | 49.75 ± 40.987 |
| S-033447: 72 hours | 17.88 ± 17.438 |
| S-033447: Day 6 | 4.72 ± 3.649 |
| S-033447: Day 10 | 1.35 ± 1.547 |
S-033447 is an active metabolite of baloxavir marboxil.
| nanograms/milliters*hour (ng/mL*hr) | Baloxavir Marboxil |
|---|---|
| Baloxavir Marboxil | NA ± NA |
| S-033447 | 5070 ± 3520 |
S-033447 is an active metabolite of baloxavir marboxil.
| nanograms/ milliters (ng/ml) | Baloxavir Marboxil |
|---|---|
| Baloxavir Marboxil | NA ± NA |
| S-033447 | 127 ± 81.0 |
S-033447 is an active metabolite of baloxavir marboxil.
| hours | Baloxavir Marboxil |
|---|---|
| Baloxavir Marboxil | NA (NA to NA) |
| S-033447 | 4.5 (2.00 to 14.5) |
S-033447 is an active metabolite of baloxavir marboxil.
| hours | Baloxavir Marboxil |
|---|---|
| Baloxavir Marboxil | NA (NA to NA) |
| S-033447 | 23.1 (13.0 to 33.4) |
Time to alleviation of influenza signs and symptoms was defined as the length of time taken from the start of treatment to the point at which all of the following criteria were met and remained for at least 21.5 hours: * A score of 0 (no problem) or 1 (minor problem) for cough and nasal symptoms for items 14 and 15 of the Canadian Acute Respiratory Illness and Flu Scale \[CARIFS\]); * A "yes" response to the following question on the CARIFS: "Since the last assessment has the participant been able to return to day care/school, or resume his or her normal daily activity in the same way as performed prior to developing the flu?"; * First return to afebrile state (tympanic temperature ≤37.2 degree Celsius \[°C\]). Median time was estimated from the Kaplan-Meier curve. Participants who withdrew prior to an event of interest or did not experience resolution of symptoms were censored at the last observation time point.
| hours | Baloxavir Marboxil |
|---|---|
| Time to Alleviation of Influenza Signs and Symptoms | 163.7 (122.5 to NA) |
Duration of fever was defined as the length of time taken by participants to return to afebrile state \[tympanic temperature ≤ 37.2°C\] and remaining so for at least 21.5 hours after onset. Participants who did not have fever at baseline or whose body temperature was not collected were excluded from the analysis. Median time was estimated from the Kaplan-Meier curve.
| hours | Baloxavir Marboxil |
|---|---|
| Duration of Fever | 23.1 (22.3 to 44.6) |
The efficacy of baloxavir marboxil was evaluated by duration of symptoms i.e., alleviation of all symptoms as defined by a score of 0 \[no problem\] or 1 \[minor problem\] and remaining so for at least 21.5 hours, for all 18 symptoms (Poor appetite; Not sleeping well; Irritable, cranky, fussy; Feels unwell; Low energy, tired; Not playing well; Crying more than usual; Needing extra care; Clinginess; Headache; Sore throat; Muscle aches or pains; Fever; Cough; Nasal congestion, runny nose; Vomiting; Not interested in what's going on; Unable to get out of bed) specified in the CARIFS questionnaire. Median time was estimated from the Kaplan-Meier curve. Participants who withdrew prior to an event of interest or did not experience resolution of symptoms were censored at the last observation time point.
| hours | Baloxavir Marboxil |
|---|---|
| Duration of Symptoms | 163.7 (71.0 to NA) |
Time to return to normal health and activity was defined by a 'Yes' response to the following question on the CARIFS: "Since the last assessment has the patient been able to return to day care/school or resume his or her normal daily activity in the same way as performed prior to developing the flu?" and remaining so for at least 21.5 hours. Median time was estimated from the Kaplan-Meier curve.Participants who withdrew prior to an event of interest or did not experience resolution of symptoms were censored at the last observation time point.
| hours | Baloxavir Marboxil |
|---|---|
| Time to Return to Normal Health and Activity | 140.7 (72.2 to NA) |
The influenza related complications include death, hospitalization, radiologically confirmed pneumonia, bronchitis, sinusitis, otitis media, encephalitis/encephalopathy, febrile seizures, myositis
| Participants | Baloxavir Marboxil |
|---|---|
| Number of Participants With Influenza-Related Complications | 0 |
The number of participants who required antibiotics for influenza related complication are reported here.
| Participants | Baloxavir Marboxil |
|---|---|
| Number of Participants Requiring Antibiotics | 0 |
Time to cessation of viral shedding by virus titer was defined as the time, in hours, between the initiation of any study treatment and first time when the influenza virus titer was below the limit of detection (0.75 log10 tissue culture infectious dose (TCID)50/milliliters \[mL\]). Participants whose virus titers did not reach the limit by the last observation time point were treated as censored at that time point. One day was converted into 24 hours. Median time was estimated from the Kaplan-Meier curve.
| hours | Baloxavir Marboxil |
|---|---|
| Time to Cessation of Viral Shedding by Virus Titer | 24.5 (24.2 to 68.6) |
Time to cessation of viral shedding by RT-PCR, in hours, was defined as the time between the initiation of study treatment and first time when the virus ribonucleic acid (RNA) by RT-PCR qualitative result was negative (no cycle threshold \[Ct\]-value detectable). Participants who did not have a negative result by the last observation time point were treated as censored at that time point. For the participants with multiple virus types, this endpoint was defined as the time between the initiation of the study treatment and first time when the virus RNA by RT-PCR qualitative result was negative for all virus types. One day was converted into 24 hours. Median time was estimated from the Kaplan -Meier curve. Participants with a positive virus RNA on Day 1 are included in this analysis.
| hours | Baloxavir Marboxil |
|---|---|
| Time to Cessation of Viral Shedding by Reverse Transcription-Polymerase Chain Reaction (RT-PCR) | 219.1 (141.6 to 695.5) |
Change from baseline in influenza virus titer (log10TCID50/mL) was defined as the change from baseline in influenza virus titer on Days 2, 4, 6, 10, and 29. If influenza virus titer was less than the lower limit of quantification (LLOQ), the virus titer was imputed as 0.749 (log10TCID50/mL). Only participants with a positive virus titer on Day 1 were included in this analysis.
| log10 TCID 50/mL | Baloxavir Marboxil |
|---|---|
| Baseline | 3.58 ± 1.81 |
| Change From Baseline at Day 2 | -2.50 ± 1.70 |
| Change From Baseline at Day 4 | -2.60 ± 1.95 |
| Change From Baseline at Day 6 | -2.43 ± 1.40 |
| Change From Baseline at Day 10 | -2.83 ± 1.81 |
| Change From Baseline at Day 29 | -1.69 ± 1.71 |
Change from baseline in the amount of virus RNA was defined as the change from baseline in the amount of virus RNA on Days 2, 4, 6 and 10. If the amount of virus RNA is less than the lower limit of quantification, the amount of virus RNA was imputed as the relevant LLOQ (log10 viral particles per mililiter (vp/mL)). If a participant was infected with multiple virus types, the sum of virus RNA (log10 vp/mL) was used for analysis. Participants with a positive virus RNA by RT-PCR on Day 1 were included in this analysis.
| log10 vp/mL | Baloxavir Marboxil |
|---|---|
| Baseline | 6.46 ± 1.91 |
| Change From Baseline at Day 2 | -2.26 ± 1.00 |
| Change From Baseline at Day 4 | -1.93 ± 1.99 |
| Change From Baseline at Day 6 | -1.76 ± 2.40 |
| Change From Baseline at Day 10 | -3.30 ± 3.46 |
Percentage of participants positive for influenza virus titer at each visit were defined as the percentage of participants whose influenza virus titer was not less than the LLOQ (0.75 log10TCID50/mL) or positive among those assessed for influenza virus titer on Days 2, 4, 6, 10 and 29. Participants with a positive influenza virus titer on Day 1 were included in this analysis.
| percentage of participants | Baloxavir Marboxil |
|---|---|
| Baseline | 100 |
| Day 2 | 40 |
| Day 4 | 20 |
| Day 6 | 30 |
| Day 10 | 0 |
| Day 29 | 0 |
Percentage of participants positive by RT-PCR at each visit was defined as the percentage of participants with a positive qualitative result among those assessed by RT-PCR on Days 2, 4, 6, 10 and 29. Participants with a positive RT-PCR result on Day 1 were included in this analysis. Percentages are rounded off.
| percentage of participants | Baloxavir Marboxil |
|---|---|
| Baseline | 100 |
| Day 2 | 92.3 |
| Day 4 | 92.3 |
| Day 6 | 64.3 |
| Day 10 | 42.9 |
| Day 29 | 0 |
AUC in virus titer was calculated using the trapezoidal method. Twenty-four hours of time was converted into one day. Participants with a positive virus titer on Day 1 were included in this analysis. The LLOQ and lower limit of detection was defined as 0.75 log10TCID50/mL for flu A and 0.75 log10TCID50/mL for flu B. If a participant was infected with multiple virus types, the sum of those virus titers will be used for analysis.
| log10 TCID 50/mL*hours | Baloxavir Marboxil |
|---|---|
| Area Under the Concentration-Time Curve (AUC) in Virus Titer | 405.23 ± 184.72 |
AUC in virus RNA (RT-PCR) was defined as AUC of change from baseline in the amount of virus RNA (RT-PCR). AUC was calculated using the trapezoidal method similar to AUC in virus titer. Participants with a positive RT-PCR result on Day 1 were subjected to this analysis. If the amount of virus RNA is less than the lower limit of quantification, the amount of virus RNA was imputed as the relevant LLOQ (log10 viral particles per mililiter (vp/mL)). If a participant was infected with multiple virus types, the sum of those the amount of virus RNA was used for analysis.
| log10 vp/mL*hours | Baloxavir Marboxil |
|---|---|
| Area Under the Curve in the Amount of Virus RNA (RT-PCR) | 779.06 ± 426.83 |
Collected over Day 1 up to Day 29. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Baloxavir Marboxil | 1/48 (2.1%) | 2/48 (4.2%) | 11/48 (22.9%) |
| Event | Baloxavir Marboxil |
|---|---|
| Lower respiratory tract infectionInfections and infestations | 1/48 |
| ChokingRespiratory, thoracic and mediastinal disorders | 1/48 |
| Event | Baloxavir Marboxil |
|---|---|
| DiarrhoeaGastrointestinal disorders | 8/48 |
| VomitingGastrointestinal disorders | 6/48 |
Safety-evaluable population included all participants who received at least one dose of treatment regardless of whether they had any follow-up assessments.
| Age, Continuous(days) | Baloxavir Marboxil |
|---|---|
| Mean | 206.5 ± 106.08 |
| Sex: Female, Male(Participants) | Baloxavir Marboxil |
|---|---|
| Female | 23 |
| Male | 25 |
| Ethnicity (NIH/OMB)(Participants) | Baloxavir Marboxil |
|---|---|
| Hispanic or Latino | 15 |
| Not Hispanic or Latino | 22 |
| Unknown or Not Reported | 11 |
| Race (NIH/OMB)(Participants) | Baloxavir Marboxil |
|---|---|
| American Indian or Alaska Native | 1 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 26 |
| White | 21 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jan 2019 to primary completion in Apr 2023, 50 months.
Results were first posted in May 2024, 1 year 1 month after primary completion.
Of 119 industry-sponsored phase 3 interventional studies under Influenza, Human, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 14. This study's 50 months is above that.
Counting every sponsor, half of 154 studies reached it within 8 months; a quarter within 4 and three quarters within 15.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Baloxavir